Ritu Baral
Stock Analyst at TD Cowen
(0.67)
# 3,462
Out of 4,667 analysts
36
Total ratings
26.09%
Success rate
-29.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $1.20 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.30 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $43.65 | +78.69% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $248.79 | +49.12% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $72.67 | +34.86% | 3 | Aug 9, 2024 | |
| SAGE Sage Therapeutics | Downgrades: Hold | $16 → $10 | $4.91 | +103.67% | 5 | Jul 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $317.09 | +22.99% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $4.52 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $110.86 | +57.86% | 1 | Mar 22, 2023 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $32 → $21 | $16.27 | +29.07% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.49 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.99 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.95 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.59 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $45.75 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.60 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.73 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.19 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $609.82 | - | 2 | Jan 12, 2018 |
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.20
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.30
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $43.65
Upside: +78.69%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $248.79
Upside: +49.12%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $72.67
Upside: +34.86%
Sage Therapeutics
Jul 30, 2024
Downgrades: Hold
Price Target: $16 → $10
Current: $4.91
Upside: +103.67%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $317.09
Upside: +22.99%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.52
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $110.86
Upside: +57.86%
ACADIA Pharmaceuticals
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $16.27
Upside: +29.07%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.49
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.99
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.95
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.59
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $45.75
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.60
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $12.73
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $1.19
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $609.82
Upside: -